CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms
Titel:
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms
Auteur:
Meyer, Sara C. Keller, Matthew D. Chiu, Sophia Koppikar, Priya Guryanova, Olga A. Rapaport, Franck Xu, Ke Manova, Katia Pankov, Dmitry O’Reilly, Richard J. Kleppe, Maria McKenney, Anna Sophia Shih, Alan H. Shank, Kaitlyn Ahn, Jihae Papalexi, Eftymia Spitzer, Barbara Socci, Nick Viale, Agnes Mandon, Emeline Ebel, Nicolas Andraos, Rita Rubert, Joëlle Dammassa, Ernesta Romanet, Vincent Dölemeyer, Arno Zender, Michael Heinlein, Melanie Rampal, Raajit Weinberg, Rona Singer Hoffman, Ronald Sellers, William R. Hofmann, Francesco Murakami, Masato Baffert, Fabienne Gaul, Christoph Radimerski, Thomas Levine, Ross L.